THALES
9.6.2020 08:02:10 CEST | Business Wire | Press release
New insights from the 2020 Thales Data Threat Report – European Edition reveal that European organisations have a false sense of security when it comes to protecting themselves, with only two-thirds (68%) seeing themselves as vulnerable, down from nine in ten (86%) in 2018. This confidence flies in the face of the findings of the survey of 509 European executives which reveals over half (52%) of organisations were breached or failed a compliance audit in 2019, raising concerns as to why a fifth (20%) intend to reduce data security spend in the next year. The findings come as workers across Europe are working from home due to COVID-19, often using personal devices which don’t have the built-in security office systems do, significantly increasing risk to sensitive data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200608005431/en/
Thales will host a webinar, “Data Security Threats and Trends in Europe” on 16 June to discuss the report in more detail. To join, please visit the registration page .
Across the board, companies are racing to digitally transform and move more applications and data to the cloud; two-fifths (37%) of European countries stated they are aggressively disrupting the markets they participate in or embedding digital capabilities to enable greater enterprise agility. A key aspect of this transformation is in the cloud becoming the leading data environment. Nearly half (46%) of all data stored by European organisations is now stored in the cloud, and with 43% of that data in the cloud being described as sensitive, it is essential that it is kept safe.
As more sensitive data is stored in cloud environments, however, data security risks increase. This is of particular concern given that 100% of businesses surveyed report that at least some of the sensitive data they are storing in the cloud is not encrypted. Only 54% of sensitive data in the cloud is protected by encryption and even less (44%) is protected by tokenisation, highlighting the disconnect between the level of investment companies are making into cybersecurity and the increasing threats they face.
Multi-Cloud Adoption Complicates Data Security
Despite the multitude of threats, businesses feel that the complexity (40%) of their environments is holding their data security capabilities back. Multi-cloud adoption is the main driver of this complexity; four-fifths (80%) of businesses are using more than one IaaS (Infrastructure as a Service) vendor, whilst a third (29%) have more than 50 SaaS (Software as a Service) applications to manage. Businesses also identified a lack of budget (30%), staff to manage (28%) and organisation buy-in/low priority (25%) as other top blockers.
“Businesses are continuing to race towards digital transformation and many are increasingly reliant on complex cloud environments, without taking a zero-trust approach. Data is more at risk than ever, whilst organisations are unwittingly creating the perfect storm for hackers by not implementing the security basics,” commented Rob Elliss, EMEA Vice President for Data Security solutions at Thales . “Unfortunately, this will result in increasing problems, particularly in a world where working remotely will be part of the new-normal, unless companies can step up to the plate when it comes to keeping data safe.”
Quantum(fying) the problem
Whilst organisations continue to look at the threat of today, many are starting to turn their attention to peril that the acceleration of computing power, quantum, could bring to them. In fact, almost all (93%) respondents are concerned quantum computing will lead to exploits being created that could expose the sensitive data they hold. What’s more, seven in 10 (69%) European organisations expect quantum to affect their cryptographic operations in the next five years.
As a result, most organisations are reacting, with a third (31%) planning to offset quantum computing threats by switching away from static encryption or symmetric cryptography. Furthermore, a similar amount (30%) plans to implement key management that supports quantum safe random number generator.
“It is clear that businesses are aware of evolving threats they face and it’s reassuring to see them acknowledging some of the key steps they need to take – including moving away from static encryption and implementing quantum-proof key management. It’s critical, though, that organisations don’t just look at threats years away, but invest in their cybersecurity processes now and see it as an integral part of their digital transformation,” Elliss concluded .
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Market page
Download HD photos
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005431/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
